Sanara Medtech Inc. (SMTI) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Reporting Period: Fiscal year ended December 31, 2025.
Company Overview: Sanara Medtech Inc. is a medical technology company focused on soft tissue repair and bone fusion products for the surgical market. Key products include CellerateRX Surgical Powder and BIASURGE Advanced Surgical Solution.
Strategic Shift: In mid-September 2025, the Company discontinued its "Tissue Health Plus" (THP) value-based wound care segment due to persistent losses and a lack of investor interest. THP operations are now classified as discontinued operations. The Company now operates as a single reportable segment focused exclusively on surgical products.
Key Financial Metrics (Continuing Operations)
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenue | $103.1 million | $86.7 million |
| Gross Profit | $95.6 million | $78.5 million |
| Gross Margin | 93% | 91% |
| Net Loss (Continuing Ops) | $(0.4) million | $(1.9) million |
| Net Loss (Total, incl. Discontinued) | $(37.6) million | $(9.9) million |
| Adjusted EBITDA | $17.0 million | $9.1 million |
| Cash and Equivalents | $16.6 million | $15.9 million |
| Long-Term Debt (Principal) | $42.8 million | $30.5 million |
Note: Total Net Loss includes a $37.2 million loss from discontinued operations, primarily driven by a $26.5 million asset impairment charge related to the THP segment.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 19% year-over-year to $103.1 million, driven by increased sales of soft tissue repair products (CellerateRX Surgical and BIASURGE) and expanded market penetration.
- Discontinued Operations: The THP segment was discontinued in Q3 2025. This resulted in a $26.5 million impairment charge on THP assets and a $1.8 million impairment charge on non-strategic surgical IP assets.
- Debt Expansion: The Company drew an additional $12.25 million under its CRG Term Loan in March 2025, bringing total principal outstanding to $42.75 million. Interest expense increased significantly due to higher debt levels and paid-in-kind (PIK) interest.
- Investments: The Company invested a total of $9.0 million in Biomimetic Innovations Limited (BMI) during 2025, acquiring exclusive U.S. distribution rights for OsStic BioAdhesive.
Guidance, Outlook, and Risks
Outlook: Management believes current cash on hand ($16.6 million) combined with expected cash flows from operations will fund growth and operations for at least the next 12 months. The focus remains on expanding the surgical product portfolio and geographic footprint.
Debt Covenants: The CRG Term Loan requires the Company to maintain annual minimum revenue of $75.0 million for 2025 (achieved) and $85.0 million for 2026. The Company was in compliance with all covenants as of December 31, 2025.
Key Risks:
- Debt Obligations: High interest rates (13.25% per annum) and significant principal repayment obligations maturing in 2029.
- Intellectual Property: The lead product, CellerateRX Surgical, lacks comprehensive patent protection and relies on trade secrets, creating competition risks.
- Regulatory: Dependence on FDA clearances for new products and compliance with healthcare fraud and abuse laws.
- Concentration: Reliance on a single manufacturer for principal revenue-producing products.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the Company meets the $85 million revenue threshold for the 2026 fiscal year to avoid default on the CRG Term Loan.
- Discontinued Operations Wind-down: Confirm that no material additional cash outflows are required to fully close the THP segment in 2026.
- Patent Protection: Assess the competitive landscape for CellerateRX Surgical given the lack of comprehensive patent coverage.
- Debt Service Capacity: Evaluate the impact of the 13.25% interest rate and PIK interest on future cash flows and liquidity.
- Product Pipeline: Monitor the regulatory timeline and commercialization potential of the OsStic BioAdhesive partnership with BMI.